与未接种疫苗人群相比，2862名医护人员接种同源和异源初免-加强的AZD1222和BNT162b2新冠疫苗后的全身反应原性。
Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population.
作者信息
Tabatabaeifar Sorosh, Vestergaard Jesper M, Würtz Else T, Hansen Karoline K, Nielsen Kent J, Schlünssen Vivi, Kolstad Henrik A
机构信息
Department of Occupational Medicine, Danish Ramazzini Centre, Aarhus University Hospital, Aarhus, Denmark.
Department of Occupational Medicine, Danish Ramazzini Centre, Goedstrup Hospital, Herning, Denmark.
出版信息
Vaccine X. 2023 Apr;13:100280. doi: 10.1016/j.jvacx.2023.100280. Epub 2023 Mar 14.
During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic reactogenicity day-by-day during two weeks for 2862 healthcare workers vaccinated with heterologous AZD1222 + BNT162b2 or homologous BNT162b2 + BNT162b2 regimens and compared prevalences of symptoms with unvaccinated healthcare workers. We found comparable systemic reactogenicity during the first week in the two vaccine regimens and no reactogenicity during the second week. Most of the symptoms returned to a level equal to the control population four days after booster vaccination.
2021年春季，丹麦将AZD1222和BNT162b2用作新冠疫苗的首剂，将BNT162b2用作加强剂。我们获取了2862名接种了异源AZD1222+BNT162b2或同源BNT162b2+BNT162b2方案的医护人员在两周内每日自我报告的全身反应原性信息，并将症状发生率与未接种疫苗的医护人员进行了比较。我们发现两种疫苗方案在第一周的全身反应原性相当，第二周没有反应原性。大多数症状在加强接种疫苗四天后恢复到与对照组人群相当的水平。
Zotero 插件